{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:01:58Z","timestamp":1746504118063,"version":"3.40.4"},"reference-count":81,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009776","name":"McMaster University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009776","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008360","name":"Hamilton Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008360","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jhepr.2025.101354","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:25:53Z","timestamp":1739521553000},"page":"101354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Salsalate improves the anti-tumor efficacy of lenvatinib in MASH-driven hepatocellular carcinoma"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1207-1557","authenticated-orcid":false,"given":"Evangelia E.","family":"Tsakiridis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0472-4615","authenticated-orcid":false,"given":"Elham","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaya","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi Ran","family":"Hannah She","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7119-5684","authenticated-orcid":false,"given":"Russta","family":"Fayyazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0040-8316","authenticated-orcid":false,"given":"James S.V.","family":"Lally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiorella","family":"Di Pastena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5164-4224","authenticated-orcid":false,"given":"Celina M.","family":"Valvano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7838-155X","authenticated-orcid":false,"given":"Daniel","family":"Del Rosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga-Demetra","family":"Biziotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Muti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8675-4422","authenticated-orcid":false,"given":"Theodoros","family":"Tsakiridis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory R.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2025.101354_bib1","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.jhep.2011.10.027","article-title":"Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace","volume":"56","author":"Baffy","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2025.101354_bib2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.canlet.2013.07.033","article-title":"NAFLD leads to liver cancer: do we have sufficient evidence?","volume":"345","author":"Duan","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jhepr.2025.101354_bib3","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhepr.2025.101354_bib4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.jhepr.2025.101354_bib5","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jhepr.2025.101354_bib6","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2021.04.049","article-title":"Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis","volume":"75","author":"Pinyol","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101354_bib7","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101354_bib8","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2025.101354_bib9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2025.101354_bib10","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2025.101354_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100591","article-title":"Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis","volume":"7","author":"Rimini","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.jhepr.2025.101354_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2022.11.017","article-title":"Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population","volume":"180","author":"Casadei-Gardini","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhepr.2025.101354_bib13","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2125.1989.tb03423.x","article-title":"Comparative analgesic and anti-inflammatory properties of sodium salicylate and acetylsalicylic acid (aspirin) in rheumatoid arthritis","volume":"27","author":"Preston","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jhepr.2025.101354_bib14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.tem.2013.06.002","article-title":"AMPK: mediating the metabolic effects of salicylate-based drugs?","volume":"24","author":"Steinberg","year":"2013","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jhepr.2025.101354_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2337\/dc07-1338","article-title":"Salsalate improves glycemia and inflammatory parameters in obese young adults","volume":"31","author":"Fleischman","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhepr.2025.101354_bib16","first-page":"40","article-title":"Evaluating the efficacy of Salsalate on prediabetic and diabetic patients with fatty liver: a randomized clinical trial","volume":"2","author":"Faghihimani","year":"2013","journal-title":"J\u00a0Res Pharm Pract"},{"key":"10.1016\/j.jhepr.2025.101354_bib17","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s00125-012-2819-3","article-title":"A\u00a0randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance","volume":"56","author":"Goldfine","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhepr.2025.101354_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-159-1-201307020-00003","article-title":"Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial","volume":"159","author":"Goldfine","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhepr.2025.101354_bib19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/jamacardio.2016.0605","article-title":"Effect of targeting inflammation with salsalate: the TINSAL-CVD randomized clinical trial on progression of coronary plaque in overweight and obese patients using statins","volume":"1","author":"Hauser","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jhepr.2025.101354_bib20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-152-6-201003160-00004","article-title":"The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial","volume":"152","author":"Goldfine","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhepr.2025.101354_bib21","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.2337\/db16-0564","article-title":"Salsalate (salicylate) uncouples mitochondria, improves glucose homeostasis, and reduces liver lipids independent of AMPK-beta1","volume":"65","author":"Smith","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.jhepr.2025.101354_bib22","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1126\/science.1215327","article-title":"The ancient drug salicylate directly activates AMP-activated protein kinase","volume":"336","author":"Hawley","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2025.101354_bib23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.celrep.2018.12.036","article-title":"Genetic liver-specific AMPK activation protects against diet-induced obesity and NAFLD","volume":"26","author":"Garcia","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhepr.2025.101354_bib24","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S2468-1253(21)00300-9","article-title":"Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study","volume":"6","author":"Cusi","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101354_bib25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41580-022-00547-x","article-title":"New insights into activation and function of the AMPK","volume":"24","author":"Steinberg","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jhepr.2025.101354_bib26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1042\/BJ20150122","article-title":"Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex\u00a0vivo through inhibition of de novo lipogenesis","volume":"469","author":"O'Brien","year":"2015","journal-title":"Biochem J"},{"key":"10.1016\/j.jhepr.2025.101354_bib27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/pros.23755","article-title":"Salicylate enhances the response of prostate cancer to radiotherapy","volume":"79","author":"Broadfield","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.jhepr.2025.101354_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101209","article-title":"Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses","volume":"14","author":"Tsakiridis","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.jhepr.2025.101354_bib29","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/1878-0261.12079","article-title":"AMPK beta1 reduces tumor progression and improves survival in p53 null mice","volume":"11","author":"Houde","year":"2017","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jhepr.2025.101354_bib30","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","article-title":"Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia","volume":"34","author":"Morrow","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2025.101354_bib31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.14740\/wjon1399","article-title":"Maximum plasma concentration of lenvatinib is useful for predicting thrombocytopenia in patients treated for hepatocellular carcinoma","volume":"12","author":"Endo","year":"2021","journal-title":"World J Oncol"},{"key":"10.1016\/j.jhepr.2025.101354_bib32","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","article-title":"A\u00a0simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer","volume":"69","author":"Tsuchida","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2025.101354_bib33","doi-asserted-by":"crossref","first-page":"15539","DOI":"10.3748\/wjg.v20.i42.15539","article-title":"Histopathology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Takahashi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2025.101354_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-3694-7_1","article-title":"Orthotopic model of hepatocellular carcinoma in mice","volume":"2769","author":"Lambertucci","year":"2024","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jhepr.2025.101354_bib35","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41575-022-00620-y","article-title":"Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101354_bib36","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s42003-023-05289-w","article-title":"The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy","volume":"6","author":"Ali","year":"2023","journal-title":"Commun Biol"},{"key":"10.1016\/j.jhepr.2025.101354_bib37","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","article-title":"Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies","volume":"23","author":"Liston","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhepr.2025.101354_bib38","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1128\/MCB.22.3.874-885.2002","article-title":"Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases","volume":"22","author":"Crosio","year":"2002","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jhepr.2025.101354_bib39","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s42003-023-05067-8","article-title":"Architectural basis for cylindrical self-assembly governing Plk4-mediated centriole duplication in human cells","volume":"6","author":"Ahn","year":"2023","journal-title":"Commun Biol"},{"key":"10.1016\/j.jhepr.2025.101354_bib40","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S1097-2765(02)00473-2","article-title":"The dissociation of cohesin from chromosomes in prophase is regulated by Polo-like kinase","volume":"9","author":"Sumara","year":"2002","journal-title":"Mol Cell"},{"key":"10.1016\/j.jhepr.2025.101354_bib41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.canlet.2014.01.018","article-title":"The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator","volume":"356","author":"Faubert","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jhepr.2025.101354_bib42","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1074\/jbc.M109.056762","article-title":"AMPK beta1 deletion reduces appetite, preventing obesity and hepatic insulin resistance","volume":"285","author":"Dzamko","year":"2010","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhepr.2025.101354_bib43","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.cmet.2018.08.020","article-title":"Inhibition of acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma","volume":"29","author":"Lally","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2025.101354_bib44","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ebiom.2018.04.009","article-title":"Activation of liver AMPK with PF-06409577 corrects NAFLD and lowers cholesterol in rodent and primate preclinical models","volume":"31","author":"Esquejo","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jhepr.2025.101354_bib45","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","article-title":"Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment","volume":"20","author":"Llovet","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101354_bib46","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s42255-024-01043-6","article-title":"An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"6","author":"Vacca","year":"2024","journal-title":"Nat Metab"},{"key":"10.1016\/j.jhepr.2025.101354_bib47","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41586-019-1373-2","article-title":"A\u00a0human liver cell atlas reveals heterogeneity and epithelial progenitors","volume":"572","author":"Aizarani","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2025.101354_bib48","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nri2762","article-title":"FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications","volume":"10","author":"Smith","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhepr.2025.101354_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008788","article-title":"Identification of Clec4b as a novel regulator of bystander activation of auto-reactive T cells and autoimmune disease","volume":"16","author":"Backdahl","year":"2020","journal-title":"Plos Genet"},{"key":"10.1016\/j.jhepr.2025.101354_bib50","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1056\/NEJMoa1615887","article-title":"CD55 deficiency, early-onset protein-losing enteropathy, and thrombosis","volume":"377","author":"Ozen","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101354_bib51","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1002\/j.1460-2075.1994.tb06836.x","article-title":"Decay-accelerating factor CD55 is identified as the receptor for echovirus 7 using CELICS, a rapid immuno-focal cloning method","volume":"13","author":"Ward","year":"1994","journal-title":"EMBO J"},{"key":"10.1016\/j.jhepr.2025.101354_bib52","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.freeradbiomed.2018.06.015","article-title":"B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD)","volume":"124","author":"Bruzzi","year":"2018","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.jhepr.2025.101354_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003731","article-title":"iRegulon: from a gene list to a gene regulatory network using large motif and track collections","volume":"10","author":"Janky","year":"2014","journal-title":"Plos Comput Biol"},{"key":"10.1016\/j.jhepr.2025.101354_bib54","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1097\/HEP.0000000000000005","article-title":"Metabolic reprogramming and its clinical implication for liver cancer","volume":"78","author":"Yang","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101354_bib55","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41573-019-0019-2","article-title":"AMP-activated protein kinase: the current landscape for drug development","volume":"18","author":"Steinberg","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jhepr.2025.101354_bib56","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S2468-1253(21)00110-2","article-title":"Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial","volume":"6","author":"Vogel","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101354_bib57","doi-asserted-by":"crossref","first-page":"30e42","DOI":"10.1128\/MCB.01169-13","article-title":"Hypoxia-inducible factor 1 regulation through cross talk between mTOR and MT1-MMP","volume":"34","author":"Sakamoto","year":"2014","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jhepr.2025.101354_bib58","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/bjc.2012.559","article-title":"Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma","volume":"108","author":"Shen","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2025.101354_bib59","doi-asserted-by":"crossref","first-page":"9149","DOI":"10.1038\/srep09149","article-title":"The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing","volume":"5","author":"Tesori","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2025.101354_bib60","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3727\/105221616X693855","article-title":"Sorafenib and 2-deoxyglucose synergistically inhibit proliferation of both sorafenib-sensitive and -resistant HCC cells by inhibiting ATP production","volume":"17","author":"Reyes","year":"2017","journal-title":"Gene Expr"},{"key":"10.1016\/j.jhepr.2025.101354_bib61","first-page":"1338","article-title":"Role of angiogenesis in the pathogenesis of NAFLD","volume":"10","author":"Lei","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jhepr.2025.101354_bib62","doi-asserted-by":"crossref","first-page":"25","DOI":"10.20892\/j.issn.2095-3941.2022.0449","article-title":"Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies","volume":"20","author":"Yao","year":"2023","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.jhepr.2025.101354_bib63","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jhep.2019.02.012","article-title":"Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease","volume":"70","author":"Hammoutene","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2025.101354_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.750044","article-title":"Gene signatures detect damaged liver sinusoidal endothelial cells in chronic liver diseases","volume":"8","author":"Verhulst","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.jhepr.2025.101354_bib65","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.22351","article-title":"Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence","volume":"48","author":"Deleve","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101354_bib66","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1053\/j.gastro.2011.12.017","article-title":"Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats","volume":"142","author":"Xie","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101354_bib67","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101354_bib68","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3390\/ijms21062061","article-title":"PPARs as metabolic regulators in\u00a0the\u00a0liver: lessons from liver-specific PPAR-null mice","volume":"21","author":"Wang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhepr.2025.101354_bib69","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41419-020-2429-9","article-title":"Imbalance in mitochondrial dynamics induced by low PGC-1alpha expression contributes to hepatocyte EMT and liver fibrosis","volume":"11","author":"Zhang","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jhepr.2025.101354_bib70","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1101\/gad.1617608","article-title":"Hypoxia regulates TSC1\/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling","volume":"22","author":"DeYoung","year":"2008","journal-title":"Genes Dev"},{"key":"10.1016\/j.jhepr.2025.101354_bib71","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41419-023-05669-4","article-title":"Sestrin2: multifaceted functions, molecular basis, and its implications in liver diseases","volume":"14","author":"Lu","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jhepr.2025.101354_bib72","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s42003-019-0624-y","article-title":"Adipocyte browning and resistance\u00a0to\u00a0obesity in mice is induced by expression of ATF3","volume":"2","author":"Cheng","year":"2019","journal-title":"Commun Biol"},{"key":"10.1016\/j.jhepr.2025.101354_bib73","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.2337\/db21-0181","article-title":"Hepatocytic activating transcription factor 3 protects against steatohepatitis via hepatocyte nuclear factor 4alpha","volume":"70","author":"Xu","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.jhepr.2025.101354_bib74","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.prp.2014.03.013","article-title":"Low expression of activating transcription factor 3 in human hepatocellular carcinoma and its clinicopathological significance","volume":"210","author":"Xiaoyan","year":"2014","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.jhepr.2025.101354_bib75","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.semcancer.2015.09.010","article-title":"The role of the transcription factor Ets1 in carcinoma","volume":"35","author":"Dittmer","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jhepr.2025.101354_bib76","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/jcb.27446","article-title":"ETS1 induces transforming growth factor beta signaling and promotes epithelial-to-mesenchymal transition in prostate cancer cells","volume":"120","author":"Rodgers","year":"2019","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.jhepr.2025.101354_bib77","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.0.CO;2-7","article-title":"Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells","volume":"169","author":"Iwasaka","year":"1996","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.jhepr.2025.101354_bib78","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41467-017-00405-x","article-title":"VEGF amplifies transcription through ETS1 acetylation to enable angiogenesis","volume":"8","author":"Chen","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2025.101354_bib79","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41419-019-1672-4","article-title":"Ets-1 deficiency alleviates nonalcoholic steatohepatitis via weakening TGF-beta1 signaling-mediated hepatocyte apoptosis","volume":"10","author":"Liu","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jhepr.2025.101354_bib80","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s13577-022-00848-5","article-title":"The roles of ETS transcription factors in liver fibrosis","volume":"36","author":"Zhang","year":"2023","journal-title":"Hum Cell"},{"key":"10.1016\/j.jhepr.2025.101354_bib81","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41573-021-00367-2","article-title":"Lipogenesis inhibitors: therapeutic\u00a0opportunities and challenges","volume":"21","author":"Batchuluun","year":"2022","journal-title":"Nat Rev Drug Discov"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925000308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925000308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T07:23:24Z","timestamp":1746429804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555925000308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2589555925000308"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101354","relation":{},"ISSN":["2589-5559"],"issn-type":[{"type":"print","value":"2589-5559"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salsalate improves the anti-tumor efficacy of lenvatinib in MASH-driven hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101354","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101354"}}